In this episode of the Oncology Brothers podcast, we dived deep into the complexities of pancreatic cancer treatment with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers

•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers

•⁠ Website: https://oncbrothers.com/

Join us as we explored:

• The challenges of diagnosing and treating pancreatic cancer, particularly in metastatic settings.

• The importance of germline testing and next-generation sequencing (NGS) in guiding treatment decisions.

• The role of neoadjuvant and adjuvant therapies, including FOLFIRINOX and Gemcitabine-based regimens.

• Strategies for managing borderline resectable disease and the significance of multidisciplinary care.

• The critical aspect of supportive care, including the use of pancreatic enzyme replacement therapy.

• Insights into treatment options for metastatic disease, including FOLFIRINOX, NALIRIFOX, and Gemcitabine-Nab-paclitaxel.

• The emerging landscape of targeted therapies for KRAS mutations and the potential of pan-RAS inhibitors.

Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving treatment algorithms for pancreatic cancer.

Don't forget to like, subscribe, and hit the notification bell for more discussions on cancer treatment and care!

#PancreaticCancer, #KRASmutation, #NeoadjuvantTherapy, #SupportiveCare, #OncBrothers

In this episode of the Oncology Brothers, we welcomed Dr. Suneel Kamath from the Cleveland Clinic to discuss the complex landscape of biliary tract cancer. While this cancer type is not the most common, it carries a poor prognosis, making it crucial for oncologists to stay informed about the latest treatment options.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• ⁠X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Join us as we explored:

• The role of surgery and adjuvant chemotherapy in early-stage biliary tract cancer.
• Frontline treatment strategies for metastatic disease, including insights from the TOPAZ-1 and KEYNOTE-966 studies.
• The importance of biomarker testing, including HER2, IDH1, and FGFR mutations, and how they influence treatment decisions.
• Management of side effects associated with various therapies, including immunotherapy and chemotherapy.
• The emerging landscape of targeted therapies and the need for more effective treatment options.

Whether you're a medical professional or someone interested in oncology, this episode provides valuable insights into the current treatment algorithms and challenges in managing biliary tract cancer.

Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!

#BiliaryTractCancer, #Cholangiocarcinoma, #Immunotherapy, #BiomarkerTesting, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of Cancer of Unknown Primary (CUP). Joined by Dr. Harry Fuentes Bayne and Dr. Thor Halfdanarson from the Mayo Clinic, they discussed the current standard of care, diagnostic workup, and treatment options for this challenging condition.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Key topics included:

• Initial diagnostic approaches for CUP, including imaging and tissue sampling
• The role of immunohistochemistry (IHC) and tumor markers in guiding treatment
• The use of next-generation sequencing (NGS) and tools like Cancer Type ID
• Treatment strategies, including chemotherapy regimens and the potential for immunotherapy
• The importance of thorough workup and palliative care in managing CUP

Whether you're a healthcare professional or simply interested in oncology, this episode provides valuable insights into the latest approaches for diagnosing and treating cancer of unknown primary origin.

Don't forget to like, subscribe, and check out our other episodes for more discussions on treatment algorithms, conference highlights, and FDA approvals. Join us on this journey through the world of oncology!

#CancerOfUnknownPrimary, #CUP, #NGS, #Immunohistochemistry, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived into the evolving treatment algorithms for bladder cancer following the latest data presented at GU ASCO 2026.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Join us as we explore:

• The role of immunotherapy in non-muscle invasive bladder cancer, highlighting the recent positive trials: CREST with Sasanlimab and POTOMAC with Durvalumab.
• Insights on the current standard of care and the implications of combining BCG with immunotherapy.
• The shift in treatment strategies for muscle-invasive bladder cancer, including the new standard of care with the EV-Pembro combination and its impact on pathologic complete response rates.
• The challenges and considerations in managing side effects associated with new therapies, as well as the importance of patient selection and coordination between urologists and medical oncologists.
• The emerging role of ctDNA in guiding treatment decisions and the ongoing discussions around the sequencing of therapies in refractory settings.

Hope you enjoy this informative discussion that aims to keep you up to date in the world of cancer treatment, here focusing on bladder cancer.

Subscribe to our channel for more episodes and discussions on the latest in oncology!

#BladderCancer, #NMIBC, #MIBC, #Immunotherapy, #GU26, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived into the transformative role of artificial intelligence (AI) in oncology and medical practice. Joined by Dr. Travis Zack, Chief Medical Officer of Open Evidence, we explored how large language models (LLMs) are revolutionizing the way clinicians access and utilize medical information.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Key topics included:

• The rapid evolution of AI in healthcare and its implications for patient care.
• How Open Evidence differentiates itself by focusing on reliable medical sources like NCCN, NEJM, and JAMA.
• The importance of integrating AI tools into clinical workflows to enhance decision-making and patient outcomes.
• The business model behind Open Evidence and the ethical considerations regarding data usage.
• Future prospects for AI in oncology, including potential integration with electronic health records (EHRs) and clinical trials.

Join us as we discuss the exciting advancements in AI technology and how they can empower oncologists to provide better care for their patients. Don't miss this insightful conversation that highlights the intersection of technology and medicine!

Subscribe to our channel for more episodes on FDA approvals, conference highlights, and treatment algorithms in oncology!

#AIinHealthcare #Oncology #MedicalAI #CancerResearch #HealthcareInnovation #OncBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we discussed current treatment landscape and updates from GU ASCO 2026, with focus on kidney cancer.

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

We were joined by Dr. Katy Beckermann, a medical oncologist from Tennessee Oncology, to discuss:

• The current standard of care for renal cell carcinoma (RCC), including adjuvant treatment options post-surgery.
• The implications of the KEYNOTE-564 study and the approval of Pembrolizumab for high-risk RCC patients.
• Insights from the LITESPARK- 022 trial, comparing Pembrolizumab with the combination of Pembrolizumab and Belzutifan in the adjuvant setting.
• The challenges of undertreatment versus overtreatment in kidney cancer therapy, including side effects and financial toxicity.
• Strategies for managing metastatic disease, including re-challenging immunotherapy and the role of IMDC criteria in treatment decisions.
• The promising data from LITESPARK-011, exploring the combination of Lenvatinib and Belzutifan in the second-line setting.

Tune in for an informative discussion that covers the latest research, clinical practices, and expert opinions in the field of kidney cancer. Don't forget to like, subscribe, and check out our other episodes for more insights into oncology!

#KidneyCancer, #RenalCellCarcinoma, #GUASCO2026, #OncBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the current treatment landscape for frontline HER2-positive gastroesophageal junction (GEJ) and gastric cancer.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers

•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers

•⁠ Website: https://oncbrothers.com/

Join us as we welcome Dr. Sunnie Kim from the University of Colorado and Dr. Samuel Cytryn from Memorial Sloan Kettering, who shared their insights on the latest advancements in HER2-targeted therapies. We discussed the pivotal TOGA and KEYNOTE-811, the promising data from the HERIZON-GEA01 study featuring Zanidatamab, and the implications of these findings for clinical practice.

Key topics included:

* Current standard of care for HER2-positive GEJ and gastric cancer

* The role of PD-L1 status in treatment decisions

* Mechanisms and efficacy of Zanidatamab compared to traditional therapies

* Management of side effects, including diarrhea and infusion-related reactions

* Future directions in HER2-targeted therapies, including T-DXd based on the DESTINY Gastric-04 trial

Don't forget to like, subscribe, and hit the notification bell for more updates on treatment algorithms, FDA approvals, and conference highlights!

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Link to gain CME credits from this activity:

https://www.gotoper.com/courses/new-precision-strategies-for-her2-gea-interpreting-new-data-to-inform-clinical-practice

Welcome to the Oncology Brothers podcast! In this episode, we discussed the current treatment landscape for prostate cancer, featuring special guest Dr. Scott Tagawa, a GU Medical Oncologist from Weill Cornell Medicine.

Listen us on:

Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966

Follow us on social media:

• X/Twitter: https://twitter.com/oncbrothers
• ⁠Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/

Join us as we explored:

• The current standard of care for localized prostate cancer, including active surveillance, surgery, and radiation.
• The significance of ADT and abiraterone in high-risk disease, supported by the STAMPEDE trial.
• The role of PSMA PET/CT in staging and how it impacts treatment decisions.
• Treatment options for castration-sensitive and castration-resistant prostate cancer, including the use of ARPi and chemotherapy.
• The importance of germline and somatic testing, especially with the recent approval of Niraparib for BRCA2-positive disease.
• Insights on managing side effects and the nuances of patient-centered care in oncology.

Whether you're a healthcare professional or someone interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help you stay informed.

Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!

#ProstateCancer, #ADT, #PSMA, #PARPinhibitor, #OncologyBrothers